Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) had its target price hoisted by equities research analysts at HC Wainwright from $25.00 to $30.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 152.95% […]
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) was upgraded by equities researchers at Jonestrading from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Benzinga reports. A number of other equities analysts have also issued reports on DCPH. Stifel Nicolaus upgraded shares of Deciphera Pharmaceuticals from a “hold” rating […]
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.03, MarketWatch Earnings reports. Deciphera Pharmaceuticals had a negative return on equity of 48.99% and a negative net margin of 127.92%. The firm […]
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) had its target price increased by Stifel Nicolaus from $20.00 to $22.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 88.68% from the company’s current price. DCPH has […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) CEO Steven L. Hoerter sold 21,573 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $12.02, for a total value of $259,307.46. Following the sale, the chief executive officer now owns 40,927 shares in the company, […]